


## Patient and procedure risk stratification backed by clinical evidence

While surgical patients may benefit from Prevena Therapy, patients at high risk for complications such as surgical site infection may see added benefit. The following uses select study data<sup>1-2</sup> to provide an illustrative guide to aid in risk stratification. This is not an all-inclusive list of risk factors. Clinicians are advised to use their clinical judgment to identify high-risk patients or high-risk procedures.



#### References

1. Willy C, Agarwal A, Andersen CA, De Santis G, Gabriel A, Grauhan O, Guerra OM, Lipsky BA, Malas MB, Mathiesen LL, Singh DP, Reddy VS. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. Int Wound J. 2017 Apr;14(2):385-398. OPEN ACCESS

2. Gabriel A, Sigalove S, Sigalove N, Storm-Dickerson T, Rice J, Maxwell P, Griffin L. The impact of closed incision negative pressure therapy on postoperative breast reconstruction outcomes. Plastic and Reconstructive Surgery Global Open. 2018 Aug; 6(8):e1880. OPEN ACCESS

# Advancing the standard of care.



### View the plastic surgery clinical evidence summary

contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2023 3M. All rights reserved. 3M and the other marks shown are marks and/or registered trademarks. Unauthorized use prohibited. US\_70-2013-1484-9

### **3M Company** 2510 Conway Ave St. Paul, MN 55144 USA

Phone 1-800-275-4524 (NPWT products) 1-800-228-3957

Web 3m.com/medical 3M<sup>™</sup> Prevena<sup>™</sup> 125 Therapy Unit and 3M<sup>™</sup> Prevena<sup>™</sup> Plus 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at mykci.com

The indication statement does not apply to the Prevena Plus 125 Therapy Unit (14-Day) that comes with the 3M<sup>™</sup> Prevena Restor<sup>™</sup> System Kits (see Prevena Restor System Instructions for Use).

**NOTE:** Specific indications, limitations,